The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth.

The potential effect of co-medication with phenobarbitone, primidone and carbamazepine on plasma and saliva concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin (4-HPPH), the major metabolite of phenytoin in man and on the incidence of phenytoin-induced gingival overgrowth was investigated in a group of 36 adult epileptic patients. There were no significant differences in plasma or saliva concentrations of 4-HPPH or phenytoin in patients prescribed phenytoin alone, compared to those who received phenytoin with either phenobarbitone, primidone, or carbamazepine. In addition, the extent and the incidence of gingival overgrowth were similar in the 2 groups. The results suggest that chronic co-medication with other anti-convulsant drugs which induce phenytoin metabolism, does not affect the plasma or saliva 4-HPPB steady-state levels, nor the degree of gingival overgrowth in adult epileptic patients on therapy with phenytoin.

[1]  R. Seymour,et al.  Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients. , 1996, Journal of periodontology.

[2]  R. Seymour,et al.  The pathogenesis of drug-induced gingival overgrowth. , 1996, Journal of clinical periodontology.

[3]  R. Seymour,et al.  Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice. , 1992, Community dentistry and oral epidemiology.

[4]  A. Hefti,et al.  Drug-induced gingival overgrowth: old problem, new problem. , 1991, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[5]  M. Peñarrocha-Diago,et al.  Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study. , 1990, Journal of periodontology.

[6]  W. Harvey,et al.  The use of human gingival fibroblasts in culture for studying the effects of phenytoin on testosterone metabolism. , 1988, Archives of oral biology.

[7]  T. Modéer,et al.  Development of phenytoin-induced gingival overgrowth in non-institutionalized epileptic children subjected to different plaque control programs. , 1987, Acta odontologica Scandinavica.

[8]  T. Modéer,et al.  The effect of a plaque control program on the development of phenytoin-induced gingival overgrowth. A 2-year longitudinal study. , 1986, Journal of clinical periodontology.

[9]  R. Seymour,et al.  The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. , 1985, Journal of clinical periodontology.

[10]  J. O’Donnell,et al.  Phenytoin induced gingival overgrowth in institutionalized epileptics. , 1984, Journal of clinical periodontology.

[11]  J. McElnay,et al.  Risk factors in phenytoin-induced gingival hyperplasia. , 1983, Journal of periodontology.

[12]  L. Marton,et al.  Simultaneous very fast liquid-chromatographic analysis of ethosuximide, primidone, phenobarbital, phenytoin, and carbamazepine in serum. , 1983, Clinical chemistry.

[13]  R. Page,et al.  The major metabolite of phenytoin (Dilantin) induces gingival overgrowth in cats. , 1978, Journal of periodontal research.

[14]  B. Whiting,et al.  Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. , 1977, British journal of clinical pharmacology.

[15]  B. G. Bibby,et al.  The effect of oral physiotherapy on dilantin gingival hyperplasia. , 1976, Journal of oral pathology.

[16]  T. M. Little,et al.  Diphenylhydantoin‐induced Gingival Hyperplasia: Its Response to Changes in Drug Dosage , 1975, Developmental medicine and child neurology.

[17]  H. Kutt.  Interactions of Antiepileptic Drugs , 1975, Epilepsia.

[18]  Angelopoulos Ap.  Diphenylhydantoin gingival hyperplasia. A clinicopathological review. 1. Incidence, clinical features and histopathology. , 1975 .

[19]  T. M. Little,et al.  Diphenylhydantoin‐induced Gingival Hyperplasia: its Relationship to Dose and Serum Level , 1973, Developmental medicine and child neurology.

[20]  O. P. Kimball.  THE TREATMENT OF EPILEPSY WITH SODIUM DIPHENYL HYDANTOINATE , 1939 .